Login / Signup

Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis.

Thomas J StrubleJuan C AlvarezScott P BrownMilan ChytilJustin S CisarRenee L DesJarlaisOla EngkvistScott A FrankDaniel R GreveDaniel J GriffinXinjun HouJeffrey W JohannesConstantine KreatsoulasBrian LahueMiriam MatheaGeorg MogkChristos A NicolaouAndrew D PalmerDaniel J PriceRichard I RobinsonSebastian SalentinLi XingTommi S JaakkolaWilliam H GreenRegina BarzilayConnor W ColeyKlavs F Jensen
Published in: Journal of medicinal chemistry (2020)
Artificial intelligence and machine learning have demonstrated their potential role in predictive chemistry and synthetic planning of small molecules; there are at least a few reports of companies employing in silico synthetic planning into their overall approach to accessing target molecules. A data-driven synthesis planning program is one component being developed and evaluated by the Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) consortium, comprising MIT and 13 chemical and pharmaceutical company members. Together, we wrote this perspective to share how we think predictive models can be integrated into medicinal chemistry synthesis workflows, how they are currently used within MLPDS member companies, and the outlook for this field.
Keyphrases
  • artificial intelligence
  • machine learning
  • big data
  • deep learning
  • small molecule
  • quality improvement
  • high throughput
  • current status
  • single cell
  • drug induced